Does Wegovy work instantly, or does it take time to show results?

The decision most people face in week three

By the third or fourth week on Wegovy, it's common to feel uncertain. The nausea from the starter dose may have settled. The scale hasn't moved much. Nothing feels dramatic. This is the moment people start asking whether the medicine is working, and it's the moment most worth understanding clearly.

Wegovy (semaglutide) is a GLP-1 receptor agonist. It mimics a gut hormone that signals fullness to the brain, slows how quickly the stomach empties, and reduces the reward response to food. These effects are real from the first injection, but their clinical expression in weight loss is slow by design. The mechanism behind how Wegovy works isn't a switch; it's a gradual recalibration of appetite that needs dose progression to deliver its full effect.

The licensed starting dose is 0.25mg, a tolerability dose. Its job is to let your system adjust, not to produce weight loss. A prescriber titrates you upward, typically every four weeks, through 0.5mg, 1.0mg, 1.7mg, and finally 2.4mg. Significant results tend to track the higher doses. Expecting dramatic change at 0.25mg is like expecting a kettle to boil with the gas at its lowest setting.

One checking habit worth building: weigh yourself at the same time each morning, after using the bathroom, before eating or drinking. Body weight fluctuates by up to 2kg day to day. A weekly average tells you far more than any single reading.

What the clinical trial evidence actually shows

The STEP 1 trial, published in the New England Journal of Medicine, followed 1,961 adults with obesity over 68 weeks. Participants lost an average of around 15% of body weight on 2.4mg semaglutide alongside lifestyle changes. That figure accumulated over more than a year, not a few weeks. The trial design itself tells you something: the researchers needed 68 weeks to capture the medicine's effect properly.

Practically, people in trials typically lose around 5–8% of body weight in the first three months, with the steeper reductions arriving in months four through twelve as doses reach maintenance. If you're comparing your week-six progress to the headline trial result, you're comparing the wrong timepoints. The timeline for when Wegovy produces results is worth reading alongside trial data for this reason.

Side effects, particularly nausea, vomiting, and changes in bowel habit, are most common in the early weeks and at each dose step. For most people they ease as the body adjusts. NHS guidance on semaglutide notes these are typically mild to moderate and transient. They are not a sign the medicine is failing, often quite the opposite.

The factors that shape how quickly you respond

Starting weight, diet quality, activity levels, sleep, stress, and whether other health conditions are present all influence the rate of response. There is no universally predictable timeline. What a prescriber can tell you is whether the pattern you're seeing falls within the expected range, which is why the relationship between patient and clinician matters throughout treatment, not just at the point of prescription.

There is a meaningful difference between whether Wegovy starts working quickly and whether it produces visible results quickly. The former is yes; the latter is no, and conflating the two leads people to stop treatment prematurely. NICE, which recommended Wegovy for use under TA875, notes that if less than 5% weight loss is achieved after six months on the maintenance dose, continuing should be reviewed, but six months at maintenance is the benchmark, not six weeks at a starter dose.

Lifestyle alongside treatment also matters more than marketing tends to acknowledge. The STEP 1 results were achieved with dietary support and activity guidance alongside the injection. Semaglutide reduces appetite; it doesn't replace the decision about what to eat when appetite returns. Understanding what Wegovy is prescribed for and what it is doing biologically helps set a realistic frame for the weeks ahead.

What this means if you're considering starting

Wegovy is a prescription-only medicine. Suitability is assessed by a GPhC-registered prescriber, and that assessment considers your BMI, health history, current medicines, and whether any contraindications apply. No legitimate service can promise a particular rate of weight loss, because individual response genuinely varies.

The semaglutide treatment overview covers eligibility in more detail. If cost is a consideration before starting, a factual breakdown of what Wegovy costs through a regulated private pharmacy is worth reading before you make any decisions. At nume, every consultation is reviewed the same day by a named, GPhC-registered prescriber (a real clinician reads your answers, not software) and treatment dispatched the same day if clinically suitable, arriving free via DPD the next working day.

Patience is not a passive thing here. It's understanding that the medicine is doing something before you can measure it. Speak to our prescribers if you'd like a clinical view of whether Wegovy is right for you and what a realistic timeline looks like for your situation.